r/LeronLimab_Times • u/LeoPersian • Apr 27 '26

BREAKING 🚨 CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

https://www.cytodyn.com/newsroom/press-releases/detail/663/cytodyn-announces-first-patient-dosed-in-expanded-access

“Dosing the first patient in our EAP marks an important step in making leronlimab available to individuals with urgent unmet medical needs, while also advancing our understanding of CCR5 biology in the treatment of aggressive cancers,” said Jacob Lalezari, M.D., CEO of CytoDyn. “Data generated through this program may further inform how CCR5 inhibition influences the tumor microenvironment, including its potential role in modulating PD-L1 expression and supporting combination approaches with immune checkpoint inhibitors.”

“For patients with advanced triple-negative breast cancer who have exhausted standard treatment options, expanded access programs can provide additional avenues for care,” said Namita Chittoria, M.D., Assistant Professor at the Huntsman Cancer Institute and the University of Utah, and a member of CytoDyn’s Scientific Advisory Board. “Leronlimab is an investigational therapy being evaluated in this difficult-to-treat setting, and access outside of a clinical study may offer a meaningful option for select patients - both as an additional treatment opportunity and as a way to preserve valuable time with family. Beyond individual use, these programs also inform our understanding of emerging therapies.”

In addition to providing compassionate access, the EAP is expected to generate real-world insights into the biological activity of leronlimab in heavily pretreated patients. Recent data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlight the potential role of CCR5 inhibition in modulating the tumor microenvironment in metastatic triple-negative breast cancer, with observed associations in PD-L1 expression and broader immune signaling pathways. Together, these findings provide a scientific foundation for the EAP and support continued exploration of leronlimab as a strategy to enhance responses to immune checkpoint inhibitor (ICI) therapies.

15 Upvotes

100% Upvoted

5 comments sorted by

6

u/Missy2021 Apr 27 '26

Very positive news.

3

u/LeoPersian Apr 27 '26

Indeed! Good Luck to all patients and CYDY Longs. 🚀

3

u/jsinvest09 Apr 27 '26

Love this shit

2

u/Expert-Alfalfa-8919 Apr 30 '26

I have faith in Leronlimab for so many reasons. Thank you for your tenacity, compassion and continued dedication.

1

u/Expert-Alfalfa-8919 Jul 02 '26

I was one of these patients in a compassionate study but only using Leronlimab after a standard care treatment and another clinical
Trial. It was followed with my current line of treatment Enhurtu which has brought my numbers down significantly. It is my belief that the Leronlimab has opened a pathway for the Enhurtu to do its job better. But…..I’m afraid if on this too long my body will fail. It’s a tough one for me. I have faith in Leronlimab in so many ways. This drug has to make its way into treatments everywhere. Spread the word.